Skip to content

Baxter International

NYSE: BAX · USD

Baxter International revenue79

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Medical Products And Therapies

Reported quarterly Infusion Therapies & Platforms. Reporting scope: Infusion Therapies And Platforms · Medical Products And Therapies · Operating Segments. Quarterly figures · USD

Medical Products And Therapies. Reported quarterly Infusion Therapies & Platforms. Reporting scope: Infusion Therapies And Platforms · Medical Products And Therapies · Operating Segments. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20261,745,000,000Filed Jul 30, 2026
Jun 30, 2025From Apr 1, 20251,649,000,000Filed Jul 30, 2026

Advanced Surgery · Medical Products And Therapies · Operating Segments revenue

Reported quarterly Advanced Surgery · Medical Products And Therapies · Operating Segments revenue. Quarterly figures · USD

Advanced Surgery · Medical Products And Therapies · Operating Segments revenue. Reported quarterly Advanced Surgery · Medical Products And Therapies · Operating Segments revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026331,000,000Filed Jul 30, 2026
Mar 31, 2026From Jan 1, 2026304,000,000Filed Apr 30, 2026
Jun 30, 2025From Apr 1, 2025296,000,000Filed Jul 30, 2026
Mar 31, 2025From Jan 1, 2025268,000,000Filed Apr 30, 2026

Healthcare Systems & Technologies · Operating Segments revenue

Reported quarterly Healthcare Systems & Technologies · Operating Segments revenue. Quarterly figures · USD

Healthcare Systems & Technologies · Operating Segments revenue. Reported quarterly Healthcare Systems & Technologies · Operating Segments revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026801,000,000Filed Jul 30, 2026
Mar 31, 2026From Jan 1, 2026705,000,000Filed Apr 30, 2026
Jun 30, 2025From Apr 1, 2025767,000,000Filed Jul 30, 2026
Mar 31, 2025From Jan 1, 2025704,000,000Filed Apr 30, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • One selected series has limited history under a revised reporting structure; it should not be spliced into the earlier business definition.
  • The selections are not a complete additive breakdown of the company.

Products & projects

Medical Products & Therapies

The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products, specialty injectable pharmaceuticals, inhaled anesthesia, drug compounding and sales of products and services provided directly through certain of our manufacturing facilities.

Filed · source for Medical Products & Therapies

Healthcare Systems & Technologies

The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices and other accessories.

Filed · source for Healthcare Systems & Technologies

Revenue history

USD millions · Fiscal periods
Jun 30, 2009 through Jun 30, 2026

Quarterly data

Baxter International quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jun 30, 20262,960, +9.6% versus FY 2026 Q1
FY 2026 Q1Mar 31, 20262,701, −9.2% versus FY 2025 Q4
FY 2025 Q4Dec 31, 20252,974, +4.9% versus FY 2025 Q3
FY 2025 Q3Sep 30, 20252,835, +0.9% versus FY 2025 Q2
FY 2025 Q2Jun 30, 20252,810, +7.0% versus FY 2025 Q1
FY 2025 Q1Mar 31, 20252,625, −4.6% versus FY 2024 Q4
FY 2024 Q4Dec 31, 20242,753, +2.0% versus FY 2024 Q3
FY 2024 Q3Sep 30, 20242,699, −29.2% versus FY 2024 Q2
FY 2024 Q2Jun 30, 20243,812, +6.1% versus FY 2024 Q1
FY 2024 Q1Mar 31, 20243,592, −7.5% versus FY 2023 Q4
FY 2023 Q4Dec 31, 20233,885, +4.8% versus FY 2023 Q3
FY 2023 Q3Sep 30, 20233,708, 0.0% versus FY 2023 Q2
FY 2023 Q2Jun 30, 20233,707, +1.6% versus FY 2023 Q1
FY 2023 Q1Mar 31, 20233,649, −2.6% versus FY 2022 Q4
FY 2022 Q4Dec 31, 20223,745, −0.7% versus FY 2022 Q3
FY 2022 Q3Sep 30, 20223,773, +0.7% versus FY 2022 Q2
FY 2022 Q2Jun 30, 20223,746, +1.1% versus FY 2022 Q1
FY 2022 Q1Mar 31, 20223,707, +5.5% versus FY 2021 Q4
FY 2021 Q4Dec 31, 20213,514, +8.9% versus FY 2021 Q3
FY 2021 Q3Sep 30, 20213,226, +4.1% versus FY 2021 Q2
FY 2021 Q2Jun 30, 20213,098, +5.2% versus FY 2021 Q1
FY 2021 Q1Mar 31, 20212,946, −7.4% versus FY 2020 Q4
FY 2020 Q4Dec 31, 20203,181, +7.0% versus FY 2020 Q3
FY 2020 Q3Sep 30, 20202,972, +9.3% versus FY 2020 Q2
FY 2020 Q2Jun 30, 20202,718, −3.0% versus FY 2020 Q1
FY 2020 Q1Mar 31, 20202,802, Change unavailable versus FY 2019 Q4
FY 2019 Q2Jun 30, 20192,840, +7.9% versus FY 2019 Q1
FY 2019 Q1Mar 31, 20192,632, −7.4% versus FY 2018 Q4
FY 2018 Q4Dec 31, 20182,841, +2.7% versus FY 2018 Q3
FY 2018 Q3Sep 30, 20182,767, −2.6% versus FY 2018 Q2
FY 2018 Q2Jun 30, 20182,842, +6.2% versus FY 2018 Q1
FY 2018 Q1Mar 31, 20182,677, −3.5% versus FY 2017 Q4
FY 2017 Q4Dec 31, 20172,774, +2.5% versus FY 2017 Q3
FY 2017 Q3Sep 30, 20172,707, +3.9% versus FY 2017 Q2
FY 2017 Q2Jun 30, 20172,605, +5.3% versus FY 2017 Q1
FY 2017 Q1Mar 31, 20172,475, −6.4% versus FY 2016 Q4
FY 2016 Q4Dec 31, 20162,645, +3.4% versus FY 2016 Q3
FY 2016 Q3Sep 30, 20162,558, −1.0% versus FY 2016 Q2
FY 2016 Q2Jun 30, 20162,585, +8.8% versus FY 2016 Q1
FY 2016 Q1Mar 31, 20162,375, −8.8% versus FY 2015 Q4
FY 2015 Q4Dec 31, 20152,603, +4.7% versus FY 2015 Q3
FY 2015 Q3Sep 30, 20152,487, −36.1% versus FY 2015 Q2
FY 2015 Q2Jun 30, 20153,893, +3.4% versus FY 2015 Q1
FY 2015 Q1Mar 31, 20153,764, −15.8% versus FY 2014 Q4
FY 2014 Q4Dec 31, 20144,472, +6.6% versus FY 2014 Q3
FY 2014 Q3Sep 30, 20144,197, −1.6% versus FY 2014 Q2
FY 2014 Q2Jun 30, 20144,264, +7.9% versus FY 2014 Q1
FY 2014 Q1Mar 31, 20143,951, −9.5% versus FY 2013 Q4
FY 2013 Q4Dec 31, 20134,368, +15.7% versus FY 2013 Q3
FY 2013 Q3Sep 30, 20133,774, +2.9% versus FY 2013 Q2
FY 2013 Q2Jun 30, 20133,669, +6.4% versus FY 2013 Q1
FY 2013 Q1Mar 31, 20133,448, −8.1% versus FY 2012 Q4
FY 2012 Q4Dec 31, 20123,753, +7.9% versus FY 2012 Q3
FY 2012 Q3Sep 30, 20123,477, −2.7% versus FY 2012 Q2
FY 2012 Q2Jun 30, 20123,572, +5.4% versus FY 2012 Q1
FY 2012 Q1Mar 31, 20123,388, −5.7% versus FY 2011 Q4
FY 2011 Q4Dec 31, 20113,594, +3.3% versus FY 2011 Q3
FY 2011 Q3Sep 30, 20113,479, −1.6% versus FY 2011 Q2
FY 2011 Q2Jun 30, 20113,536, +7.7% versus FY 2011 Q1
FY 2011 Q1Mar 31, 20113,284, −6.1% versus FY 2010 Q4
FY 2010 Q4Dec 31, 20103,498, +8.5% versus FY 2010 Q3
FY 2010 Q3Sep 30, 20103,224, +0.9% versus FY 2010 Q2
FY 2010 Q2Jun 30, 20103,194, +9.1% versus FY 2010 Q1
FY 2010 Q1Mar 31, 20102,927, −15.6% versus FY 2009 Q4
FY 2009 Q4Dec 31, 20093,470, +10.3% versus FY 2009 Q3
FY 2009 Q3Sep 30, 20093,145, +0.7% versus FY 2009 Q2
FY 2009 Q2Jun 30, 20093,123, Change unavailable versus FY 2009 Q1
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.
Annual and quarterly differences
  • FY 2014 · Total revenue: annual 16,671, quarter sum 16,884 USD millions.
  • FY 2015 · Total revenue: annual 9,968, quarter sum 12,747 USD millions.
  • FY 2022 · Total revenue: annual 15,113, quarter sum 14,971 USD millions.
  • FY 2023 · Total revenue: annual 14,813, quarter sum 14,949 USD millions.
  • FY 2024 · Total revenue: annual 10,636, quarter sum 12,856 USD millions.